"The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
- Patient Information:
Details with Side Effects
Confusion, lethargy, and depression have been reported in a limited number of patients receiving continuous intravenous infusion of ZANOSAR (streptozocin) for 5 days. Patients should be informed that there may be a potential risk in driving or using complex machinery.
Last reviewed on RxList: 2/26/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Zanosar Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.